Hussein Yassine, MD, Keck School of Medicine at the University of Southern California, Los Angeles, CA, provides an overview of the novel peptide CS6253, which shows promise in reducing the risk of Alzheimer’s disease (AD). CS6253 improves the intake of lipids into APOE to produce high-density lipoprotein (HDL)-like particles, a process impaired in APOE4 carriers. In animal models of AD, CS6253 injections increased HDL-like particle production, correlating with reduced AD biomarkers. A Phase I clinical trial (NCT05965414) confirmed the peptide’s safety, paving the way for a Phase II trial to assess its role in AD prevention or treatment. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
